FundedIQ
Health Care

NuvoAir: Funding, Investors & Team (Oct 2026)

NuvoAir is a leading digital health company for chronic disease management and decentralized clinical trials. The NuvoAir Home platform blends connected devices with high-touch care coordination services to enable patients and their providers to proactively manage chronic conditions, resulting in better outcomes and lower costs. NuvoAir Home currently supports thousands of patients worldwide with COPD, cystic fibrosis, severe asthma, IPF, ALS, and muscular dystrophy. NuvoAir's decentralized clinical trial solution has been used in over 30 studies globally across all phases of drug development.

www.nuvoair.com LinkedIn Boston, United States 51-100 employees
Total raised
$23.0M
Rounds
2
Latest
Series A
Jan 2022

NuvoAir has raised $23.0M across 2 funding rounds on record, the most recent a Series A of $11.0M announced in Jan 2022.

That round is above the $4.9M median round size for Health Care companies tracked on FundedIQ over the last two years.

NuvoAir Company Profile and Key Stats

Total funding raised
$23.0M
across 2 rounds on record
Funding rounds on record
2
Latest funding round
Series A
$11.0M in Jan 2022
Employees
51-100
reported band
Headquarters
Boston, United States

Latest funding round on record: Jan 2022.

NuvoAir Funding Rounds

Date
Round
Amount
Series A
$11.0M
Undisclosed round
$12.0M

NuvoAir raised $12.0M in an undisclosed round announced in Jun 2021.

7 months later, a Series A of $11.0M was announced in Jan 2022.

NuvoAir Founders and Leadership Team

Name
Role
Contact
Lorenzo Consoli
CEO
Locked

Contact details for the NuvoAir team: 1 of 1 has an email address on file.

Start 14-day free trial →

NuvoAir Funding Compared to Other Health Care Startups

Segment
Companies
Median round
3,659
$4.9M
30,234
$7.6M
8,558
$15M

NuvoAir's latest round of $11.0M is above the median round in Health Care. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like NuvoAir in Health Care and Boston

Companies Similar to NuvoAir

Using technology and the best professionals, Wally, a membership-based dental care service, offers proactive,…

Series A $25.0M

PreciseDx is a unique Cancer Risk Stratification company that offers personalized risk information by…

Undisclosed round $3.7M

General Medicine provides a convenient and straightforward way to access top-quality healthcare services with…

Series B $120M

Forty million men in the US and over 500 million worldwide suffer from urinary obstruction related to benign…

Series D $52.0M

SedMed provides medical devices that support safer toileting transfers and help prevent falls for individuals…

Undisclosed round $4.0M

Aptatek is developing cutting edge technologies for portable disease management devices that will improve…

Undisclosed round —

Flow Medical offers multi-function catheters to aid in the diagnosis and treatment of venous thromboembolic…

Undisclosed round $150k

Light Wave Dental Management offers management services for high-quality dental offices in Virginia.…

Undisclosed round $1.0M

For health care systems and payers focused on improving maternal outcomes and health equity, our product is a…

Seed $250k

Tempo Therapeutics creates materials that are designed for regenerative medicine, with a focus on being…

Undisclosed round $14.5M

Vibronix was established by Dr. Ji-Xin Cheng and Dr. Pu Wang at Purdue University with the goal of offering…

Series B $14.9M

People with chronic diseases can live their best lives thanks to Vheda Health. We concentrate on three areas…

Undisclosed round $47.0M

NuvoAir Funding FAQs

What does NuvoAir do?

NuvoAir is a leading digital health company for chronic disease management and decentralized clinical trials. The NuvoAir Home platform blends connected devices with high-touch care coordination services to enable patients and their providers to proactively manage chronic conditions, resulting in better outcomes and lower costs. NuvoAir Home currently supports thousands of patients worldwide with COPD, cystic fibrosis, severe asthma, IPF, ALS, and muscular dystrophy. NuvoAir's decentralized clinical trial solution has been used in over 30 studies globally across all phases of drug development.

How much funding has NuvoAir raised?

NuvoAir has raised $23.0M across 2 rounds on record. The most recent is a Series A of $11.0M announced in Jan 2022.

When did NuvoAir last raise funding?

NuvoAir's most recent funding round on record is a Series A of $11.0M, announced in Jan 2022.

Who is the CEO of NuvoAir?

Lorenzo Consoli is listed as CEO at NuvoAir.

Where is NuvoAir headquartered?

NuvoAir is based in Boston, Massachusetts, United States.

How many employees does NuvoAir have?

NuvoAir is in the 51-100 employee band.

How does NuvoAir's funding compare to other Health Care startups?

NuvoAir's latest round of $11.0M is above the $4.9M median round size for Health Care companies on FundedIQ across 3,659 tracked companies over the last two years.

About FundedIQ's NuvoAir Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for NuvoAir is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.

Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.